Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

NCT00324155 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

681

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Ipilimumab
DRUG: Placebo
DRUG: Dacarbazine

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]